Methodological and reporting considerations for reflex FGFR testing in urinary tract carcinomas
Am J Clin Pathol · 03.03.2026 · 165 (3)
DOI: 10.1093/ajcp/aqag006 ↗Kurz gefasst
Editorial in der Zeitschrift Am J Clin Pathol, online erschienen am 24.03.2026. Verfasst von Jun-Gu Lin und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth Affiliated Hospital of Southwest Medical University, Meishan, Sichuan, P.R. China. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
TO THE EDITOR We read with great interest the study by Nguyen et al.1 which reported the detection rate for FGFR1-4 alterations in a real-world, dual-institution cohort of urinary tract carcinomas. This study highlights an enrichment in upper tract tumors and lung metastases, offering evidence to inform predictive FGFR testing guidelines and targeted therapy strategies. However, some methodological and substantive issues warrant further examination. The reporting of FGFR alteration rates lacks internal consistency. The Abstract states that actionable FGFR alterations occur in 23.8% of upper tract and 13.8% of lower tract carcinomas, whereas Table 2 lists corresponding values of 22.2% and 10.0%, respectively. For any FGFR alterations, Table 2 reports 23.6% vs 13.4%. These discrepancies suggest endpoint misalignment. Furthermore, Figure 1 classifies 1 FGFR3 amplification as actionable, which is inconsistent with current indications approved by the US Food and Drug Administration (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s010lbl.pdf). FGFR2 mutations are depicted as n = 2 in the figure, whereas the main text reports 3 cases. In Table 1, the age group of ≥55 years is listed as having only 34 patients; however, with a total of 366 patients and 17 under the age of 55, the correct number may be 349. It should be noted that a significant sample size imbalance exists in the age groups (17 in the
Autor:innen und Institutionen
- The Fourth Affiliated Hospital of Southwest Medical University, Meishan, Sichuan, P.R. China.
ORCID-Profile: Gang Tian
Zitieren
APA
Lin, J. G., Lin, J. G., & Tian, G. (2026). Methodological and reporting considerations for reflex FGFR testing in urinary tract carcinomas. Am J Clin Pathol, 165(3). https://doi.org/10.1093/ajcp/aqag006
Vancouver
Lin JG, Lin JG, Tian G. Methodological and reporting considerations for reflex FGFR testing in urinary tract carcinomas. Am J Clin Pathol. 2026;165(3). doi:10.1093/ajcp/aqag006
BibTeX
@article{Lin2026,
author = {Lin, Jun-Gu and Lin, Jun-Gu and Tian, Gang},
title = {Methodological and reporting considerations for reflex FGFR testing in urinary tract carcinomas},
journal = {Am J Clin Pathol},
year = {2026},
volume = {165},
number = {3},
doi = {10.1093/ajcp/aqag006}
}
EUVIMED